Literature DB >> 26504450

A Reminder of Methylene Blue's Effectiveness in Treating Vasoplegic Syndrome after On-Pump Cardiac Surgery.

Joshua Manghelli, Lisa Brown, Hany B Tadros, Nabil A Munfakh.   

Abstract

The inflammatory response induced by cardiopulmonary bypass decreases vascular tone, which in turn can lead to vasoplegic syndrome. Indeed the hypotension consequent to on-pump cardiac surgery often necessitates vasopressor and intravenous fluid support. Methylene blue counteracts vasoplegic syndrome by inhibiting the formation of nitric oxide. We report the use of methylene blue in a 75-year-old man who developed vasoplegic syndrome after cardiac surgery. After the administration of methylene blue, his hypotension improved to the extent that he could be weaned from vasopressors. The use of methylene blue should be considered in patients who develop hypotension refractory to standard treatment after cardiac surgery.

Entities:  

Keywords:  Cardiopulmonary bypass/adverse effects; hemodynamics/drug effects; hypotension/drug therapy; methylene blue/administration & dosage/therapeutic use; nitric oxide/antagonists & inhibitors; shock, vasodilatory/physiopathology; vasoconstrictor agents/therapeutic use; vasodilation/physiology; vasoplegia/etiology/therapy; vasopressors/therapeutic use

Mesh:

Substances:

Year:  2015        PMID: 26504450      PMCID: PMC4591896          DOI: 10.14503/THIJ-14-4470

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  13 in total

Review 1.  Vasoplegia during cardiac surgery: current concepts and management.

Authors:  Gregory W Fischer; Mathew A Levin
Journal:  Semin Thorac Cardiovasc Surg       Date:  2010

2.  Low systemic vascular resistance after cardiopulmonary bypass: incidence, etiology, and clinical importance.

Authors:  T Carrel; L Englberger; P Mohacsi; P Neidhart; J Schmidli
Journal:  J Card Surg       Date:  2000 Sep-Oct       Impact factor: 1.620

3.  Methylene blue, a nitric oxide inhibitor, prevents haemodialysis hypotension.

Authors:  G Peer; E Itzhakov; Y Wollman; T Chernihovsky; I Grosskopf; D Segev; D Silverberg; M Blum; D Schwartz; A Iaina
Journal:  Nephrol Dial Transplant       Date:  2001-07       Impact factor: 5.992

4.  Preoperative methylene blue administration in patients at high risk for vasoplegic syndrome during cardiac surgery.

Authors:  Ertuğrul Ozal; Erkan Kuralay; Vedat Yildirim; Selim Kilic; Cengiz Bolcal; Nezihi Kücükarslan; Celalettin Günay; Ufuk Demirkilic; Harun Tatar
Journal:  Ann Thorac Surg       Date:  2005-05       Impact factor: 4.330

5.  Risk factors for post-cardiopulmonary bypass vasoplegia in patients with preserved left ventricular function.

Authors:  A Mekontso-Dessap; R Houël; C Soustelle; M Kirsch; D Thébert; D Y Loisance
Journal:  Ann Thorac Surg       Date:  2001-05       Impact factor: 4.330

6.  Methylene blue: the drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass?

Authors:  Rainer G Leyh; Theo Kofidis; Martin Strüber; Stefan Fischer; Karsten Knobloch; Bjoern Wachsmann; Christian Hagl; Andre R Simon; Axel Haverich
Journal:  J Thorac Cardiovasc Surg       Date:  2003-06       Impact factor: 5.209

7.  Vasoplegic syndrome after open heart surgery.

Authors:  W J Gomes; A C Carvalho; J H Palma; C A Teles; J N Branco; M G Silas; E Buffolo
Journal:  J Cardiovasc Surg (Torino)       Date:  1998-10       Impact factor: 1.888

8.  Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery.

Authors:  Ricardo L Levin; Marcela A Degrange; Gustavo F Bruno; Carlos D Del Mazo; Daniel J Taborda; Jorge J Griotti; Fernando J Boullon
Journal:  Ann Thorac Surg       Date:  2004-02       Impact factor: 4.330

9.  Early on-cardiopulmonary bypass hypotension and other factors associated with vasoplegic syndrome.

Authors:  Matthew A Levin; Hung-Mo Lin; Javier G Castillo; David H Adams; David L Reich; Gregory W Fischer
Journal:  Circulation       Date:  2009-10-12       Impact factor: 29.690

10.  Inhibition of nitric oxide synthesis by methylene blue.

Authors:  B Mayer; F Brunner; K Schmidt
Journal:  Biochem Pharmacol       Date:  1993-01-26       Impact factor: 5.858

View more
  3 in total

1.  Methylene Blue Is a Guanylate Cyclase Inhibitor That Does Not Interfere with Nitric Oxide Synthesis.

Authors:  Paulo Roberto B Evora
Journal:  Tex Heart Inst J       Date:  2016-02-01

Review 2.  Vasoplegia after cardiopulmonary bypass: A narrative review of pathophysiology and emerging targeted therapies.

Authors:  Theresa J Barnes; Maxwell A Hockstein; Craig S Jabaley
Journal:  SAGE Open Med       Date:  2020-06-25

3.  The additional use of methylene blue has a decatecholaminisation effect on cardiac vasoplegic syndrome after cardiac surgery.

Authors:  Walter Petermichl; Michael Gruber; Ina Schoeller; Kwahle Allouch; Bernhard M Graf; York A Zausig
Journal:  J Cardiothorac Surg       Date:  2021-07-28       Impact factor: 1.637

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.